Creative use of the priority review voucher by public and not-for-profit actors delivers the first new FDA-approved treatment for river blindness in 20 years
Gespeichert in:
| Veröffentlicht in: | PLoS neglected tropical diseases 2018-11, Vol.12 (11), p.e0006837 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 11 |
| container_start_page | e0006837 |
| container_title | PLoS neglected tropical diseases |
| container_volume | 12 |
| creator | Olliaro, Piero L Kuesel, Annette C Halleux, Christine M Sullivan, Mark Reeder, John C |
| description | |
| doi_str_mv | 10.1371/journal.pntd.0006837 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2252305633</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A564080736</galeid><doaj_id>oai_doaj_org_article_a2bcdca835654a6a84ce56956c5cf6ea</doaj_id><sourcerecordid>A564080736</sourcerecordid><originalsourceid>FETCH-LOGICAL-c624t-709e6eedb37bf7890e63a1d235557cc9541d6e0a35e699783aa46706a7ac8a2b3</originalsourceid><addsrcrecordid>eNptktGK1DAUhoso7rr6BqIBQbzpmDZN2t4sDKOrCwve6HU4TU9nMnSSmqQj8zC-q-lOd5mRJRcJyf9_5-TnJMnbjC4yVmaft3Z0BvrFYEK7oJSKipXPksusZjzNS8afn5wvklfebynlNa-yl8kFowWr64JeJn9XDiHoPZLRI7EdCRskg9PW6XAgDvca_5C9HdUGHWkOZBibXisCpiXGhrSzLh2c7XQgoIJ1nrTYR1o8TKBOOx-IiYibL8sUhijdY0vCVHOHJpDoJ27Sk4g1rUHviTYkp-SA4Pzr5EUHvcc3836V_Lr5-nP1Pb378e12tbxLlciLkJa0RoHYNqxsurKqKQoGWZszznmpVM2LrBVIgXEUdV1WDKAQJRVQgqogb9hV8v7IHXrr5Zysl3nOc0a5YCwqbo-K1sJWxoB24A7Sgpb3F9atJbigVY8yAlWroGJc8AIEVIVCLmouFFedQIis67na2OywVTEIB_0Z9PzF6I1c270UOSvzqoqATzPA2d8j-iB32ivsezBox9h3xniW19l93x_-kz79u1m1hvgBbTob66oJKpdcFLSiJRNRtXhCFVeLO62swU7H-zPDxxPDBqEPG2_7MWhr_LmwOAqVs9477B7DyKicpv2hazlNu5ynPdrenQb5aHoYb_YP6ZL-JQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2252305633</pqid></control><display><type>article</type><title>Creative use of the priority review voucher by public and not-for-profit actors delivers the first new FDA-approved treatment for river blindness in 20 years</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><source>Public Library of Science (PLoS)</source><creator>Olliaro, Piero L ; Kuesel, Annette C ; Halleux, Christine M ; Sullivan, Mark ; Reeder, John C</creator><creatorcontrib>Olliaro, Piero L ; Kuesel, Annette C ; Halleux, Christine M ; Sullivan, Mark ; Reeder, John C</creatorcontrib><identifier>ISSN: 1935-2735</identifier><identifier>ISSN: 1935-2727</identifier><identifier>EISSN: 1935-2735</identifier><identifier>DOI: 10.1371/journal.pntd.0006837</identifier><identifier>PMID: 30439940</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Actors ; Animals ; Aquatic insects ; Blindness ; Care and treatment ; Chemotherapy ; Diagnosis ; Disease ; Diseases ; Drug approval ; Drug Approval - legislation & jurisprudence ; Drug Approval - organization & administration ; Drug development ; Drug dosages ; Drugs ; FDA approval ; Filaricides - pharmacology ; Financial institutions ; Financing ; Food ; Global health ; Humans ; Incentives ; Infections ; Medical sciences ; Medicine ; Medicine and Health Sciences ; Neglected Diseases - drug therapy ; Neglected Diseases - parasitology ; New products ; Nonprofit organizations ; Onchocerca - drug effects ; Onchocerca - physiology ; Onchocerciasis ; Onchocerciasis, Ocular - drug therapy ; Organizations ; Pharmaceutical industry ; Philanthropy ; Poverty ; Profits ; Public finance ; R&D ; Registration ; Research & development ; Research and analysis methods ; Return on investment ; Returns ; Reviews ; Rivers ; Skin ; Social Sciences ; Training ; Tropical climate ; Tropical diseases ; United States ; United States Food and Drug Administration ; Vaccines ; Viewpoints</subject><ispartof>PLoS neglected tropical diseases, 2018-11, Vol.12 (11), p.e0006837</ispartof><rights>COPYRIGHT 2018 Public Library of Science</rights><rights>2018 Olliaro et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2018 Olliaro et al 2018 Olliaro et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c624t-709e6eedb37bf7890e63a1d235557cc9541d6e0a35e699783aa46706a7ac8a2b3</citedby><cites>FETCH-LOGICAL-c624t-709e6eedb37bf7890e63a1d235557cc9541d6e0a35e699783aa46706a7ac8a2b3</cites><orcidid>0000-0003-3049-1034</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237288/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237288/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79343,79344</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30439940$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Olliaro, Piero L</creatorcontrib><creatorcontrib>Kuesel, Annette C</creatorcontrib><creatorcontrib>Halleux, Christine M</creatorcontrib><creatorcontrib>Sullivan, Mark</creatorcontrib><creatorcontrib>Reeder, John C</creatorcontrib><title>Creative use of the priority review voucher by public and not-for-profit actors delivers the first new FDA-approved treatment for river blindness in 20 years</title><title>PLoS neglected tropical diseases</title><addtitle>PLoS Negl Trop Dis</addtitle><subject>Actors</subject><subject>Animals</subject><subject>Aquatic insects</subject><subject>Blindness</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Diagnosis</subject><subject>Disease</subject><subject>Diseases</subject><subject>Drug approval</subject><subject>Drug Approval - legislation & jurisprudence</subject><subject>Drug Approval - organization & administration</subject><subject>Drug development</subject><subject>Drug dosages</subject><subject>Drugs</subject><subject>FDA approval</subject><subject>Filaricides - pharmacology</subject><subject>Financial institutions</subject><subject>Financing</subject><subject>Food</subject><subject>Global health</subject><subject>Humans</subject><subject>Incentives</subject><subject>Infections</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine and Health Sciences</subject><subject>Neglected Diseases - drug therapy</subject><subject>Neglected Diseases - parasitology</subject><subject>New products</subject><subject>Nonprofit organizations</subject><subject>Onchocerca - drug effects</subject><subject>Onchocerca - physiology</subject><subject>Onchocerciasis</subject><subject>Onchocerciasis, Ocular - drug therapy</subject><subject>Organizations</subject><subject>Pharmaceutical industry</subject><subject>Philanthropy</subject><subject>Poverty</subject><subject>Profits</subject><subject>Public finance</subject><subject>R&D</subject><subject>Registration</subject><subject>Research & development</subject><subject>Research and analysis methods</subject><subject>Return on investment</subject><subject>Returns</subject><subject>Reviews</subject><subject>Rivers</subject><subject>Skin</subject><subject>Social Sciences</subject><subject>Training</subject><subject>Tropical climate</subject><subject>Tropical diseases</subject><subject>United States</subject><subject>United States Food and Drug Administration</subject><subject>Vaccines</subject><subject>Viewpoints</subject><issn>1935-2735</issn><issn>1935-2727</issn><issn>1935-2735</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNptktGK1DAUhoso7rr6BqIBQbzpmDZN2t4sDKOrCwve6HU4TU9nMnSSmqQj8zC-q-lOd5mRJRcJyf9_5-TnJMnbjC4yVmaft3Z0BvrFYEK7oJSKipXPksusZjzNS8afn5wvklfebynlNa-yl8kFowWr64JeJn9XDiHoPZLRI7EdCRskg9PW6XAgDvca_5C9HdUGHWkOZBibXisCpiXGhrSzLh2c7XQgoIJ1nrTYR1o8TKBOOx-IiYibL8sUhijdY0vCVHOHJpDoJ27Sk4g1rUHviTYkp-SA4Pzr5EUHvcc3836V_Lr5-nP1Pb378e12tbxLlciLkJa0RoHYNqxsurKqKQoGWZszznmpVM2LrBVIgXEUdV1WDKAQJRVQgqogb9hV8v7IHXrr5Zysl3nOc0a5YCwqbo-K1sJWxoB24A7Sgpb3F9atJbigVY8yAlWroGJc8AIEVIVCLmouFFedQIis67na2OywVTEIB_0Z9PzF6I1c270UOSvzqoqATzPA2d8j-iB32ivsezBox9h3xniW19l93x_-kz79u1m1hvgBbTob66oJKpdcFLSiJRNRtXhCFVeLO62swU7H-zPDxxPDBqEPG2_7MWhr_LmwOAqVs9477B7DyKicpv2hazlNu5ynPdrenQb5aHoYb_YP6ZL-JQ</recordid><startdate>20181101</startdate><enddate>20181101</enddate><creator>Olliaro, Piero L</creator><creator>Kuesel, Annette C</creator><creator>Halleux, Christine M</creator><creator>Sullivan, Mark</creator><creator>Reeder, John C</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7SS</scope><scope>7T2</scope><scope>7T7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>F1W</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>H95</scope><scope>H97</scope><scope>K9.</scope><scope>L.G</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-3049-1034</orcidid></search><sort><creationdate>20181101</creationdate><title>Creative use of the priority review voucher by public and not-for-profit actors delivers the first new FDA-approved treatment for river blindness in 20 years</title><author>Olliaro, Piero L ; Kuesel, Annette C ; Halleux, Christine M ; Sullivan, Mark ; Reeder, John C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c624t-709e6eedb37bf7890e63a1d235557cc9541d6e0a35e699783aa46706a7ac8a2b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Actors</topic><topic>Animals</topic><topic>Aquatic insects</topic><topic>Blindness</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Diagnosis</topic><topic>Disease</topic><topic>Diseases</topic><topic>Drug approval</topic><topic>Drug Approval - legislation & jurisprudence</topic><topic>Drug Approval - organization & administration</topic><topic>Drug development</topic><topic>Drug dosages</topic><topic>Drugs</topic><topic>FDA approval</topic><topic>Filaricides - pharmacology</topic><topic>Financial institutions</topic><topic>Financing</topic><topic>Food</topic><topic>Global health</topic><topic>Humans</topic><topic>Incentives</topic><topic>Infections</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine and Health Sciences</topic><topic>Neglected Diseases - drug therapy</topic><topic>Neglected Diseases - parasitology</topic><topic>New products</topic><topic>Nonprofit organizations</topic><topic>Onchocerca - drug effects</topic><topic>Onchocerca - physiology</topic><topic>Onchocerciasis</topic><topic>Onchocerciasis, Ocular - drug therapy</topic><topic>Organizations</topic><topic>Pharmaceutical industry</topic><topic>Philanthropy</topic><topic>Poverty</topic><topic>Profits</topic><topic>Public finance</topic><topic>R&D</topic><topic>Registration</topic><topic>Research & development</topic><topic>Research and analysis methods</topic><topic>Return on investment</topic><topic>Returns</topic><topic>Reviews</topic><topic>Rivers</topic><topic>Skin</topic><topic>Social Sciences</topic><topic>Training</topic><topic>Tropical climate</topic><topic>Tropical diseases</topic><topic>United States</topic><topic>United States Food and Drug Administration</topic><topic>Vaccines</topic><topic>Viewpoints</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Olliaro, Piero L</creatorcontrib><creatorcontrib>Kuesel, Annette C</creatorcontrib><creatorcontrib>Halleux, Christine M</creatorcontrib><creatorcontrib>Sullivan, Mark</creatorcontrib><creatorcontrib>Reeder, John C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ASFA: Aquatic Sciences and Fisheries Abstracts</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) Professional</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PLoS neglected tropical diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Olliaro, Piero L</au><au>Kuesel, Annette C</au><au>Halleux, Christine M</au><au>Sullivan, Mark</au><au>Reeder, John C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Creative use of the priority review voucher by public and not-for-profit actors delivers the first new FDA-approved treatment for river blindness in 20 years</atitle><jtitle>PLoS neglected tropical diseases</jtitle><addtitle>PLoS Negl Trop Dis</addtitle><date>2018-11-01</date><risdate>2018</risdate><volume>12</volume><issue>11</issue><spage>e0006837</spage><pages>e0006837-</pages><issn>1935-2735</issn><issn>1935-2727</issn><eissn>1935-2735</eissn><cop>United States</cop><pub>Public Library of Science</pub><pmid>30439940</pmid><doi>10.1371/journal.pntd.0006837</doi><orcidid>https://orcid.org/0000-0003-3049-1034</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1935-2735 |
| ispartof | PLoS neglected tropical diseases, 2018-11, Vol.12 (11), p.e0006837 |
| issn | 1935-2735 1935-2727 1935-2735 |
| language | eng |
| recordid | cdi_plos_journals_2252305633 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access; Public Library of Science (PLoS) |
| subjects | Actors Animals Aquatic insects Blindness Care and treatment Chemotherapy Diagnosis Disease Diseases Drug approval Drug Approval - legislation & jurisprudence Drug Approval - organization & administration Drug development Drug dosages Drugs FDA approval Filaricides - pharmacology Financial institutions Financing Food Global health Humans Incentives Infections Medical sciences Medicine Medicine and Health Sciences Neglected Diseases - drug therapy Neglected Diseases - parasitology New products Nonprofit organizations Onchocerca - drug effects Onchocerca - physiology Onchocerciasis Onchocerciasis, Ocular - drug therapy Organizations Pharmaceutical industry Philanthropy Poverty Profits Public finance R&D Registration Research & development Research and analysis methods Return on investment Returns Reviews Rivers Skin Social Sciences Training Tropical climate Tropical diseases United States United States Food and Drug Administration Vaccines Viewpoints |
| title | Creative use of the priority review voucher by public and not-for-profit actors delivers the first new FDA-approved treatment for river blindness in 20 years |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T18%3A30%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Creative%20use%20of%20the%20priority%20review%20voucher%20by%20public%20and%20not-for-profit%20actors%20delivers%20the%20first%20new%20FDA-approved%20treatment%20for%20river%20blindness%20in%2020%20years&rft.jtitle=PLoS%20neglected%20tropical%20diseases&rft.au=Olliaro,%20Piero%20L&rft.date=2018-11-01&rft.volume=12&rft.issue=11&rft.spage=e0006837&rft.pages=e0006837-&rft.issn=1935-2735&rft.eissn=1935-2735&rft_id=info:doi/10.1371/journal.pntd.0006837&rft_dat=%3Cgale_plos_%3EA564080736%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2252305633&rft_id=info:pmid/30439940&rft_galeid=A564080736&rft_doaj_id=oai_doaj_org_article_a2bcdca835654a6a84ce56956c5cf6ea&rfr_iscdi=true |